TCGA-DK-A1A7-01A-11R-A13Y-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 18.39684625
- os_event
- false
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.510
- KRAS_SIGNALING_DN+0.500
- SPERMATOGENESIS+0.350
- APICAL_SURFACE+0.100
- KRAS_SIGNALING_UP+0.070
- BILE_ACID_METABOLISM+0.030
- COAGULATION+0.030
- MYOGENESIS+0.010
- XENOBIOTIC_METABOLISM+0.000
- ESTROGEN_RESPONSE_LATE-0.060
Top 10 suppressed
- PROTEIN_SECRETION-0.630
- MYC_TARGETS_V1-0.610
- UNFOLDED_PROTEIN_RESPONSE-0.600
- MITOTIC_SPINDLE-0.570
- TGF_BETA_SIGNALING-0.560
- MTORC1_SIGNALING-0.550
- INTERFERON_ALPHA_RESPONSE-0.540
- MYC_TARGETS_V2-0.520
- PI3K_AKT_MTOR_SIGNALING-0.520
- DNA_REPAIR-0.510
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CF-A3MF-01A-12R-A21D-07 | — | — | 0.990 |
| 2 | MNG597 | — | — | 0.980 |
| 3 | MDT-AP-0706 | Med | Medulloblastoma | 0.979 |
| 4 | 08e3d239-3d8a-4eee-9e08-ac2bcb3f2619 | — | — | 0.975 |
| 5 | msclc569389_S35.txt | — | cohortMD1 | 0.974 |
| 6 | SRR1394566 | GTEX | — | 0.973 |
| 7 | MNG1259 | — | — | 0.969 |
| 8 | c7d31245-5d71-4a23-8a33-4f83c4718e20 | — | — | 0.968 |
| 9 | TCGA-CF-A8HX-01A-11R-A36F-07 | — | — | 0.967 |
| 10 | SRR1366141 | GTEX | — | 0.966 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.510 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.500 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.350 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.070 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| COAGULATION | 0.030 | Binimetinib | — uncovered |
| MYOGENESIS | 0.010 | Inavolisib | — uncovered |